Placebo, Prozac and PLoS: Significant lessons for psychopharmacology

Journal of Psychopharmacology

Volumn 25, Issue 10, 2011, Pages 1277-1288

  Horder, Jamie ^a   Matthews, Paul ^b   Waldmann, Robert ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MILTON KEYNES GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antidepressants; meta analysis; placebo

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; EFFECT SIZE; EVIDENCE BASED MEDICINE; HAMILTON SCALE; HUMAN; META ANALYSIS; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSION; FLUOXETINE; HUMANS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES;

EID: 82955241435     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110372544     Document Type: Review

References (39)

1. American Psychiatric Association (2000) Handbook of psychiatric measures, Washington, D.C.
2. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight?. Am J Psychiatry. 2004 ; 161: 2163-2177 (Pubitemid 39587278)
3. Bech P. Is the antidepressive effect of second-generation antidepressants a myth?. Psychol Med. 2009 ; 40 (2). 181-186
4. Broich K. Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. Eur Neuropsychopharmacol. 2009 ; 19: 305-308
5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 ; 373 (9665). 746-758
6. Cohen J Statistical power analysis for the behavioral sciences. 1988 ) Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Lawrence Earlbaum Associates, Hillsdale, NJ: Lawrence Earlbaum Associates ; 1988 :
7. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000 ; 34: 3-10 (Pubitemid 30006935)
8. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003 ; 361: 653-661 (Pubitemid 36246547)
9. Hegerl U, Mergl R. The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol. 2010 ; 24 (4). 445-448
10. Ioannidis JP. Ranking antidepressants. Lancet. 2009 ; 373: 1759-1760
11. Kelly BD. Do new-generation antidepressants work?. Ir Med J. 2008 ; 101: 155-155
12. Khan A, Khan S. Placebo response in depression: a perspective for clinical practice. Psychopharmacol Bull. 2008 ; 41: 91-98
13. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002 ; 22: 40-45 (Pubitemid 34101291)
14. Kirsch I. Antidepressant drugs 'work', but they are not clinically effective. Br J Hosp Med (Lond). 2008 ; 69 (6). 359-359
15. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008 ; 5: e45 - e45
16. Kirsch I, Moncrieff J. Clinical trials and the response rate illusion. Contemp Clin Trials. 2007 ; 28: 348-351 (Pubitemid 46755021)
17. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The Emperor's New Drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat. 2002 ; 5 ( 1 ):
18. Kirsch I, Sapirstein G. Listening to Prozac but Hearing Placebo: a Meta-Analysis of Antidepressant Medication. Prev Treat. 1998 ; 1 (2). Article 2a - Article 2a
19. Lima MS, Moncrieff J. Drugs versus placebo for dysthymia. Cochrane Database Syst Rev. 2000 ; 4: CD001130 - CD001130
20. Maier W, Philipp M. Comparative analysis of observer depression scales. Acta Psychiatr Scand. 1985 ; 72: 239-245 (Pubitemid 16257029)
21. Mathew SJ, Charney DS. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009 ; 166: 140-145
22. McAllister-Williams RH. Do antidepressants work? A commentary on 'Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration' by Kirsch et al. Evid Based Ment Health. 2008a ; 11: 66-68
23. McAllister-Williams RH. Misinterpretation of randomized trial evidence: Do antidepressants work?. Br J Hosp Med (Lond). 2008b ; 69: 246-247
24. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. Br Med J. 2003 ; 326: 1171-1173 (Pubitemid 36649049)
25. Moller HJ. Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci. 2001 ; 251 (suppl 2). II13-20
26. Moller HJ. Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci. 2008 ; 258: 451-455
27. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. Br Med J. 2005 ; 331: 155-157 (Pubitemid 41003178)
28. Montgomery SA. The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol. 1999 ; 9: 271-276
29. National Institute for Clinical Excellence (2004) Depression: Management of depression in primary and secondary care. London: Clinical practice guideline No 23.
30. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008 ; 63: 424-434
31. Nichols AL, Maner JK. The good-subject effect: investigating participant demand characteristics. J Gen Psychol. 2008 ; 135: 151-165
32. Nutt DJ, Malizia A. Why does the world have such a 'down' on antidepressants?. J Psychopharmacol. 2008 ; 22: 223-226 (Pubitemid 351847444)
33. Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol. 2008 ; 22: 3-6
34. Parker G. Antidepressants on trial: how valid is the evidence?. Br J Psychiatry. 2009 ; 19: 1-3
35. Parker G, Anderson IM, Haddad P. Clinical trials of antidepressant medications are producing meaningless results. Br J Psychiatry. 2003 ; 183: 102-104 (Pubitemid 36963134)
36. Santen G, Gomeni R, Danhof M, Pasqua OD. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. J Psychiatr Res. 2008 ; 42 (12). 1000-1009
37. The Cochrane Collaboration (2008) The Cochrane handbook for systematic reviews of interventions. Version 5.0.0. Higgins JPT and Green S (eds.) Available from www.cochrane-handbook.org.
38. Turner EH, Rosenthal R. Efficacy of antidepressants. Br Med J. 2008 ; 336: 516-517
39. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002 ; 287: 1840-1847 (Pubitemid 34303629)